RetractedTrialScientific reports2019

Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

S F Jørgensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.